Actively Recruiting
Study of Continuing or Stopping Somatostatin Analog Treatment in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors Starting Second-Line Therapy
Led by University Hospital, Antwerp · Updated on 2024-06-14
270
Participants Needed
19
Research Sites
260 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of continuing versus stopping somatostatin analog SSA treatment in patients with advanced, non-functional gastroenteropancreatic GEP neuroendocrine tumors NET who have progressive disease despite first-line SSA therapy. This Phase 4, multi-national, open-label, randomized, controlled trial divides eligible patients into two groups based on their second-line therapy choice peptide receptor radionuclide therapy PRRT or targeted therapy. The study aims to understand the impact of continuing SSA treatment alongside second-line therapies, stratifying patients by tumor grade and study site.
CONDITIONS
Brief Title
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Research Team
M
Marc U Peeters, MD
T
Timon Vandamme, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
